Publications Office of the EU
Exploris 480 mass spectrometer - EU tenders
DisplayCustomHeader
MyPortal
Language Selector
English
BasketSummary
Procurement Detail Actions Portlet

Utilities

Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates CPV codes deduced from the text of the procedure

- indicates text translated automatically in your browsing language

Exploris 480 mass spectrometer

Overview
  • Today
    11/05/2026
Status
Submission closed
Type of contract
Supplies
Subject for Renewal
No
Buyer
Universitätsklinikum Hamburg-Eppendorf
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: DE600 Hamburg
Business sector (Main CPV)
38000000 Laboratory, optical and precision equipments (excl. glasses)
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
Not available
Procedure details
Tender reference number
0374_2025-09
Description

The client considers that the supply of a new mass spectrometer with the functionalities necessary for the client can only be provided by the selected company. The system was selected on the basis of the following unique technical feature: The Orbitrap Exploris 480 is characterized by an industry-unique mass resolution of up to 480,000 (at m/z 200). This high resolution is crucial for the differentiation of isobaric compounds – i.e. molecules with identical nominal mass, such as leucine and isoleucine (Δm = 0.003 Da). Thanks to the precise mass determination (accuracy < 1 ppm), the system allows the unique identification of such isomers, which is indispensable for the analysis of complex biological samples. Compared to competing systems, which typically achieve a maximum resolution of 120,000-140,000, these fail in differentiating closely adjacent masses. In paediatric research, where low abundant biomarkers (e.g. cytokines, metabolites) need to be detected in complex samples (e.g. plasma, fibroblast lysates), the Orbitrap Exploris 480 offers a key advantage: The combination of high resolution and excellent sensitivity (LOD < 1 fg/μL) enables the detection of molecules that cannot be detected on other systems. Quantitative analyses (e.g. protein expression studies) also show the superiority of the system: Overlapping isotope peaks, which lead to misinterpretations on conventional devices, are cleanly separated by the ultra-high resolution. This allows precise quantification (CV < 5%) even in complex dies. Without the unique resolution of 480,000 of the Orbitrap Exploris 480, central research approaches would be impossible. These include the quantification of low abundant proteins in patient fibroblasts (requires LOD < 10 fg/μL) and the analysis of post-translational modifications (e.g. phosphorylation) with < 1 ppm mass accuracy. The Orbitrap Exploris 480 with Vanquish Neo is technically unique and indispensable for the mentioned research projects.

Submission Method
Not available
Tenders may be submitted
Not available
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Place of performance
DE Deutschland
DE600 Hamburg
CPV code

38000000 - Laboratory, optical and precision equipments (excl. glasses)

38433000 - Spectrometers

Award method
Not available
Estimated value
Not available
Final contracted value
Not available
Award of contract
Not available
Documents
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.